Acura Pharmaceuticals has been granted a patent for an abuse deterrent pharmaceutical composition. The composition includes a pharmaceutically active ingredient, an acid soluble ingredient, and a buffering ingredient to retard release of the active ingredient when ingested in excess. GlobalData’s report on Acura Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Acura Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Acura Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Acura Pharmaceuticals's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Abuse deterrent pharmaceutical composition with delayed release mechanism

Source: United States Patent and Trademark Office (USPTO). Credit: Acura Pharmaceuticals Inc

A newly granted patent (Publication Number: US11857629B2) discloses an abuse-deterrent pharmaceutical composition designed to prevent misuse or abuse of drugs. The composition includes a pharmaceutically active ingredient, an acid-soluble ingredient, and a buffering ingredient. The buffering ingredient plays a crucial role in suppressing the peak plasma concentration (Cmax) of the active ingredient when the composition is ingested in excess of the therapeutic dosage, thereby deterring abuse.

Furthermore, the buffering ingredient also extends the time (Tmax) until the peak plasma concentration (Cmax) of the active ingredient is reached when ingested in excess of the appropriate dosage. This delay in release aims to prevent rapid onset of effects when the composition is misused. The patent emphasizes the importance of the buffering ingredient in retarding the release of the active ingredient, especially in cases where the drug is susceptible to abuse or has a narrow therapeutic index. Overall, the composition is designed to provide a safer alternative for pharmaceuticals prone to misuse, ensuring a controlled release mechanism that discourages abuse while maintaining therapeutic efficacy.

To know more about GlobalData’s detailed insights on Acura Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies